{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T13:30:28Z","timestamp":1785850228924,"version":"3.56.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To retrospectively evaluate the visual and anatomic outcomes of intravitreal faricimab monotherapy in treatment na\u00efve neovascular age-related macular degeneration (nAMD) patients presenting with large submacular hemorrhage (SMH).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with neovascular age-related macular degeneration (nAMD) presenting with at least 50% subretinal hemorrhage (SRH) involving the fovea between March 2023 and June 2025 were identified. Patients with greater than 750 microns of total thickness of subfoveal hemorrhage were excluded. Patients were treated with faricimab as first line therapy utilizing a treat-extend-stop protocol for one year. Spectral domain optical coherence tomography (SD-OCT) and fluorescein angiogram (FA)\/ indocyanine green angiography (ICG) were used to determine total CNV lesion size, SRH area size, and macular thickness. Visual acuity and SD-OCT were also obtained at each visit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Six patients were identified that met the inclusion criteria. There were two males and four females. The average age of was 83.0 years. Prior to treatment, the average total CNV lesion size was 19.7mm\n                      <jats:sup>2<\/jats:sup>\n                      and the average hemorrhage area was 14.5 mm\n                      <jats:sup>2<\/jats:sup>\n                      for an average SRH percentage of 73.8%. The average central macular thickness (CMT) prior to treatment was 478.3 \u03bcm and the average CMT 6 months after beginning treatment was 306.8 \u03bcm (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.0031). The average CMT 1 year after treatment was 259.0 \u03bcm (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.0017). Average ETDRS letters before treatment was 48.8 letters {Snellen equivalent 20\/138} with a range of 23\u201370 letters. Average ETDRS letters after 6 months of treatment was 60.3 letters {Snellen equivalent 20\/63} with a range of 42 to 76 letters (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.017). Average ETDRS letters after 1 year of treatment was 64.7 letters {Snellen equivalent 20\/50} with a range from 26 to 80 letters (\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.014). The average number of injections was 9.3 at 1 year.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with nAMD complicated by at least 50% SRH, there was improved vision and decreased CMT. On average, vision improved by 16.4 ETDRS letters and improved on average from 20\/138 to 20\/50 on Snellen after 1 year of faricimab monotherapy. These patients may be successfully managed with faricimab monotherapy. While visual acuity overall improved, some patients had more improvement than others likely due to the location of the CNV.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40942-025-00771-5","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T16:25:21Z","timestamp":1763828721000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Neovascular age-related macular degeneration complicated by large submacular hemorrhage managed with faricimab monotherapy"],"prefix":"10.1186","volume":"11","author":[{"given":"Jerald","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hema","family":"Ramkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean D.","family":"Adrean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,22]]},"reference":[{"issue":"7","key":"771_CR1","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40265-022-01713-3","volume":"82","author":"M Shirley","year":"2022","unstructured":"Shirley M, Faricimab. First Approval Drugs. 2022;82(7):825\u201330. https:\/\/doi.org\/10.1007\/s40265-022-01713-3.","journal-title":"First Approval Drugs"},{"issue":"9","key":"771_CR2","doi-asserted-by":"publisher","first-page":"a006650","DOI":"10.1101\/cshperspect.a006650","volume":"2","author":"G Thurston","year":"2012","unstructured":"Thurston G, Daly C. The complex role of Angiopoietin-2 in the Angiopoietin-Tie signaling pathway. Cold Spring Harb Perspect Med. 2012;2(9):a006650\u2013006650. https:\/\/doi.org\/10.1101\/cshperspect.a006650.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"4","key":"771_CR3","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.preteyeres.2008.05.001","volume":"27","author":"JS Penn","year":"2008","unstructured":"Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res. 2008;27(4):331\u201371. https:\/\/doi.org\/10.1016\/j.preteyeres.2008.05.001.","journal-title":"Prog Retin Eye Res"},{"issue":"16","key":"771_CR4","doi-asserted-by":"publisher","first-page":"9424","DOI":"10.3390\/ijms23169424","volume":"23","author":"S Liberski","year":"2022","unstructured":"Liberski S, Wichrowska M, Koci\u0119cki J. Aflibercept versus faricimab in the treatment of neovascular Age-Related macular degeneration and diabetic macular edema: A review. Int J Mol Sci. 2022;23(16):9424. https:\/\/doi.org\/10.3390\/ijms23169424.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"771_CR5","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s00417-024-06695-4","volume":"263","author":"V Chaudhary","year":"2025","unstructured":"Chaudhary V, Mar F, Amador MJ, et al. Emerging clinical evidence of a dual role for Ang-2 and VEGF-A Blockade with faricimab in retinal diseases. Graefes Arch Clin Exp Ophthalmol. 2025;263(5):1239\u201347. https:\/\/doi.org\/10.1007\/s00417-024-06695-4.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"771_CR6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0039-6257(97)00089-1","volume":"42","author":"MA Hochman","year":"1997","unstructured":"Hochman MA, Seery CM, Zarbin MA. Pathophysiology and management of subretinal hemorrhage. Surv Ophthalmol. 1997;42(3):195\u2013213. https:\/\/doi.org\/10.1016\/S0039-6257(97)00089-1.","journal-title":"Surv Ophthalmol"},{"issue":"7","key":"771_CR7","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.ophtha.2018.01.012","volume":"125","author":"SD Adrean","year":"2018","unstructured":"Adrean SD, Chaili S, Ramkumar H, Pirouz A, Grant S. Consistent Long-Term therapy of neovascular Age-Related macular degeneration managed by 50 or more Anti\u2013VEGF injections using a Treat-Extend-Stop protocol. Ophthalmology. 2018;125(7):1047\u201353. https:\/\/doi.org\/10.1016\/j.ophtha.2018.01.012.","journal-title":"Ophthalmology"},{"issue":"7","key":"771_CR8","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.oret.2020.02.012","volume":"4","author":"SD Adrean","year":"2020","unstructured":"Adrean SD, Morgenthien E, Ghanekar A, Ali FS. Subretinal fibrosis in HARBOR varies by choroidal neovascularization subtype. Ophthalmol Retina. 2020;4(7):752\u20134. https:\/\/doi.org\/10.1016\/j.oret.2020.02.012.","journal-title":"Ophthalmol Retina"},{"issue":"2","key":"771_CR9","doi-asserted-by":"publisher","first-page":"378","DOI":"10.4103\/NRR.NRR-D-23-01642","volume":"20","author":"J Zhang","year":"2025","unstructured":"Zhang J, Sheng X, Ding Q, Wang Y, Zhao J, Zhang J. Subretinal fibrosis secondary to neovascular age-related macular degeneration: mechanisms and potential therapeutic targets. Neural Regen Res. 2025;20(2):378\u201393. https:\/\/doi.org\/10.4103\/NRR.NRR-D-23-01642.","journal-title":"Neural Regen Res"},{"issue":"10326","key":"771_CR10","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(22)00010-1.","journal-title":"Lancet"},{"issue":"2","key":"771_CR11","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ophtha.2014.08.020","volume":"122","author":"MM Altaweel","year":"2015","unstructured":"Altaweel MM, Daniel E, Martin DF, et al. Outcomes of eyes with lesions composed of >\u200950% blood in the comparison of Age-Related macular degeneration treatments trials (CATT). Ophthalmology. 2015;122(2):391\u2013e3985. https:\/\/doi.org\/10.1016\/j.ophtha.2014.08.020.","journal-title":"Ophthalmology"},{"key":"771_CR12","doi-asserted-by":"publisher","unstructured":"Dimopoulos S, Leitritz MA, Ziemssen F, Voykov B, Bartz-Schmidt KU, Gelisken F. Submacular predominantly hemorrhagic choroidal neovascularization: resolution of bleedings under anti-VEGF therapy. Clin ophthalmol. Published Online August 2015:1537. https:\/\/doi.org\/10.2147\/OPTH.S87919","DOI":"10.2147\/OPTH.S87919"},{"issue":"4","key":"771_CR13","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1136\/bjo.2005.085001","volume":"90","author":"RP Singh","year":"2006","unstructured":"Singh RP. Management of subretinal macular haemorrhage by direct administration of tissue plasminogen activator. Br J Ophthalmol. 2006;90(4):429\u201331. https:\/\/doi.org\/10.1136\/bjo.2005.085001.","journal-title":"Br J Ophthalmol"},{"key":"771_CR14","unstructured":"Wong CW. Management of Submacular Hemorrhage. Am Acad Ophthalmol. Published online May 1, 2018."},{"issue":"4","key":"771_CR15","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.sjopt.2016.10.002","volume":"30","author":"E Abdelkader","year":"2016","unstructured":"Abdelkader E, Yip KP, Cornish KS. Pneumatic displacement of submacular haemorrhage. Saudi J Ophthalmol. 2016;30(4):221\u20136. https:\/\/doi.org\/10.1016\/j.sjopt.2016.10.002.","journal-title":"Saudi J Ophthalmol"},{"issue":"3","key":"771_CR16","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/00055735-200106000-00011","volume":"12","author":"JL Borrillo","year":"2001","unstructured":"Borrillo JL, Regillo CD. Treatment of subretinal hemorrhages with tissue plasminogen activator. Curr Opin Ophthalmol. 2001;12(3):207\u201311. https:\/\/doi.org\/10.1097\/00055735-200106000-00011.","journal-title":"Curr Opin Ophthalmol"},{"key":"771_CR17","doi-asserted-by":"publisher","unstructured":"Ali Said Y, Dewilde E, Stalmans P. Visual outcome after vitrectomy with subretinal tPA injection to treat submacular hemorrhage secondary to age-related macular degeneration or macroaneurysm. Oishi A, ed. J Ophthalmol. 2021;2021:1\u20135. https:\/\/doi.org\/10.1155\/2021\/3160963","DOI":"10.1155\/2021\/3160963"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00771-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-025-00771-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00771-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:26:43Z","timestamp":1781616403000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40942-025-00771-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,22]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["771"],"URL":"https:\/\/doi.org\/10.1186\/s40942-025-00771-5","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,22]]},"assertion":[{"value":"30 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study adhered to the tenets of the Declaration of Helsinski. Local institutional review board (IRB) approval was obtained, IRB00012874; 2025-002-RCOC. All data was collected in accordance with the Health Insurance Portability and Accountability Act (HIPAA). Written informed consent was not required given the retrospective nature of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"American Society of Retina Specialists annual meeting, Long Beach, CA 7\/31\/2025.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Meeting presentation"}},{"value":"Jerald Lim, B.S.: None. Hannah Cho, B.A.: None. Hema Ramkumar, M.D.: Grant support from Adverum, Alexion, Amgen, Apellis, Eyepoint Pharmaceuticals, Genentech, Iveric Bio, Kodiak Life Sciences, NGM Pharmaceuticals, Ocular Therepeutix Opthea, Regeneron Pharmaceuticals, Inc., REGENXBIO, and Rezolute; served as a consultant\/advisor for Genentech and Ocular Therepeutix. Sean D. Adrean, M.D.: Grant support from Adverum, Alexion, Amgen, Apellis, Eyepoint Pharmaceuticals, Genentech, Iveric Bio, Kodiak Life Sciences, NGM Pharmaceuticals, Ocular Therepeutix, Opthea, Regeneron Pharmaceuticals, Inc., REGENXBIO, and Rezolute; served as a consultant\/advisor for Adverum, Apellis, Genentech, and REGENXBIO.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"142"}}